Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems

Normanno, Nicola; Apostolides, Kathi; Lorenzo, Francesco De; Beer, Philip; Henderson, Raymond; Sullivan, Richard; Biankin, Andrew V.; Horgan, Denis; Lawler, Mark

doi:10.1016/j.semcancer.2021.08.002

Cited by 38 publications

(28 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cancer biomarkers are secreted into tissues and biological fluids, allowing early detection by minimally invasive and non-invasive methods [ 27 , 28 ]. Here, we can include all analytical devices and methods that can be applied for the detection and/or monitoring of biomarkers from biological samples that can be collected in a minimally invasive manner (saliva, perspiration, tears), such as portable and wearable electrochemical detection devices.…”

Section: Biomarkers Involved In Inflammatory Diseasesmentioning

confidence: 99%

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

et al. 2022

View full text Add to dashboard Cite

Recent years have shown that the diagnosis and monitoring of biomarkers involved in inflammatory-associated medical conditions such as cancer, neurological disorders, viral infections, or daily physical activities offer real benefits in increasing the quality of medical care and patient life quality. In this context, the use of integrated and portable platforms as point-of-care testing devices for biomedical analysis to enable early disease diagnosis and monitoring, which can be successfully used even at the patient’s bed, is an emergency nowadays. The development of low-cost, miniaturized, and portable, user-friendly devices that provide an answer in a timely manner, such as electrochemical sensors, is relevant for the elaboration of point-of-care testing devices. This review focuses on the recent progress in bioanalysis of both specific biomarkers and inflammatory-associated biomarkers present in several diseases like neoplasia, severe neurological disorders, viral infections, and usual physical activity and provides an overview of the state of the art over the most recent electrochemical (bio)sensors for the detection of inflammation-related biomarkers. Future perspectives of point-of-care testing to improve healthcare management are also discussed. Graphical abstract

show abstract

Section: Biomarkers Involved In Inflammatory Diseasesmentioning

confidence: 99%

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In the last decade, a better understanding of the complex cancer molecular biology led to the identification of gene alterations that, by one side, favor cancer cell proliferation and growth, on the other hand, could represent an element of vulnerability. Indeed, the identification of a molecular driver, susceptible to target therapy, allowed the development of a “sartorial” and personalized treatment for a subset of patients with oncogene-addicted tumors, including BTC [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

Ciardiello

Maiorano

Parente

et al. 2022

IJMS

Self Cite

View full text Add to dashboard Cite

Biliary tract cancers (BTC) represent a heterogeneous and aggressive group of tumors with dismal prognosis. For a long time, BTC has been considered an orphan disease with very limited therapeutic options. In recent years a better understanding of the complex molecular landscape of biology is rapidly changing the therapeutic armamentarium. However, while 40–50% of patients there are molecular drivers susceptible to target therapy, for the remaining population new therapeutic options represent an unsatisfied clinical need. The role of immunotherapy in the continuum of treatment of patients with BTC is still debated. Despite initial signs of antitumor-activity, single-agent immune checkpoint inhibitors (ICIs) demonstrated limited efficacy in an unselected population. Therefore, identifying the best partner to combine ICIs and predictive biomarkers represents a key challenge to optimize the efficacy of immunotherapy. This review provides a critical analysis of completed trials, with an eye on future perspectives and possible biomarkers of response.

show abstract

“…The revolutionary precision that molecular diagnostics can bring to healthcare and the dramatic improvements it can bring to oncology screening and treatment are now widely recognized [ 1 ]. However, progress is hampered by several logistical and technical factors.…”

Section: Introductionmentioning

confidence: 99%

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring

et al. 2022

Self Cite

View full text Add to dashboard Cite

Liquid biopsy (LB) is a minimally invasive method which aims to detect circulating tumor-derived components in body fluids. It provides an alternative to current cancer screening methods that use tissue biopsies for the confirmation of diagnosis. This paper attempts to determine how far the regulatory, policy, and governance framework provide support to LB implementation into healthcare systems and how the situation can be improved. For that reason, the European Alliance for Personalised Medicine (EAPM) organized series of expert panels including different key stakeholders to identify different steps, challenges, and opportunities that need to be taken to effectively implement LB technology at the country level across Europe. To accomplish a change of patient care with an LB approach, it is required to establish collaboration between multiple stakeholders, including payers, policymakers, the medical and scientific community, and patient organizations, both at the national and international level. Regulators, pharma companies, and payers could have a major impact in their own domain. Linking national efforts to EU efforts and vice versa could help in implementation of LB across Europe, while patients, scientists, physicians, and kit manufacturers can generate a pull by undertaking more research into biomarkers.

show abstract

Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems

Cited by 38 publications

References 40 publications

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

Accelerating the Development and Validation of Liquid Biopsy for Early Cancer Screening and Treatment Tailoring

Contact Info

Product

Resources

About